DILIsym®

Quantitative systems toxicology (QST) software
for drug-induced liver injury (DILI)

Click here for an overview presentation on DILIsym

Choose a Module:

What is the PBPK Submodel?

PBPK Scaffold for Compound W. The scaffold for Compound X is identical, while Compound Y is a simplified representation with only two compartments: the volume of distribution and the liver.

The DILIsym PBPK submodel was originally developed to help predict liver concentrations for exemplar compounds.  The model is only a basic PBPK framework.  GastroPlus®, a far more advanced PBPK software platform, can be employed to support simulations with DILIsym as well, by using DILIsym’s “Specify Data” feature.  This feature allows users to specify time-course inputs based on external simulation results, e.g. liver concentrations, to be used in their toxicity predictions.  Thus, the “Specify Data” feature enables use of mature, data-rich platforms like GastroPlus (with machine-learning inputs from ADMET Predictor®) in tandem with DILIsym.

However, some cases may require the built-in PBPK framework within DILIsym (e.g. acetaminophen toxicity).  The basic DILIsym PBPK submodel framework consists of a physiologically based pharmacokinetic (PBPK) model used to calculate the tissue distribution and elimination of a particular compound. The dosing routes include oral, intraperitoneal, and intravenous (bolus and infusion). Tissues explicitly represented include the liver, gut (small intestine), muscle, and blood. The ‘other’ tissue compartment is comprised of all other tissues not explicitly mentioned. Distribution to liver, gut, muscle, and ‘other’ tissue can be represented by either perfusion (flow)-limited or permeability-limited models. Saturable, transporter-mediated uptake and efflux processes are represented in the liver tissue. The transporter-mediated uptake of compound into the liver can be induced or repressed by liver compound. The process of oral absorption includes the stomach and lumen compartments to allow for gastric emptying effects. The size of the liver and the amount of blood are subject to change from their baseline values based on the amount of cellular necrosis.

The primary method of clearance from circulation for many xenobiotics is biotransformation in the liver. The metabolites are eventually eliminated in the urine or bile. The periportal, midlobular, and centrilobular acinar regions are each represented to enable representation of the assymetric distribution of the enzymes responsible for drug metabolism, such as the cytochrome P450 (CYP450) family of enzymes. The compound metabolites move from the periportal zone into the midlobular zone, then into the centrilobular zone, and then into the blood, in the direction of blood flow. Both the parent compound and its metabolite can be converted to a reactive metabolite (RM), which can bind to proteins and form protein adducts, bind to glutathione (GSH), or be deactivated.

Learn more about other submodels within DILIsym:

What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?

To learn more on the DILIsym® Applications in Drug Development, register for our 2021 DILIsym® Panel-driven Webinar on April 29. Join us for Q&A session with Dr. Vlad Coric (CEO of Biohaven Pharmaceuticals), Dr. Lorenzo Pellegrini (COO of Palladio Biosciences), Dr. Paul B. Watkins, a hepatologist and DILI experts. Register Now